Purchase this article with an account.
Jay Chhablani, Daren Hanumunthadu, Elon HC van Dijk, Sunila Dumpala, Bindu Rajesh, Ayesha Jabeen, Asiya Jabeen, Momin Ansari, Pooja Mehta, Shilpi Shah, Chintan Sarvaiya, Catherine Meyerele, Lihteh Wu, Alay Banker, Giridhar Anantharaman, Camiel JF Boon; Choroidal layer thickness in central serous retinopathy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1295.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate medium (MCVT) and large (LCVT) choroidal vessel thickness in eyes with acute and chronic central serous retinopathy (CSR) in comparison with fellow eyes and age-matched controls.
Retrospective analysis of enhanced-depth imaging optical coherence tomography (EDI-OCT) scans of patients with acute and chronic CSR and age-matched healthy subjects. Manual measurements of subfoveal choroidal thickness (SFCT), MCVT and LCVT at subfoveal and 750μm nasal and temporal to fovea locations were done by single observer using the ImageJ® software. One-way ANOVA with post hoc Tukey’s test was used for statistical analysis.
132 eyes of 96 subjects with CSR including 53 eyes with acute CSR, 43 with chronic CSR as well as and additional 36 fellow eyes. Mean age of CSR subjects was 45.5 (±8.5) years with 81 males. Thirty eyes of 30 age-matched subjects were included with mean age of 44.8 ± 9.4 years with 5 males. SFCT of acute CSR was significantly larger than fellow (p = 0.01) and normal eyes (p = 0.0001), but not eyes with chronic CSR. Subfoveal LCVT in acute CSR was more than normal eyes (p = 0.02). Subfoveal MCVT of acute CSR eyes was significantly more than fellow (p = 0.04) and control (p = 0.03) eyes, whilst mean thickness in eyes with chronic CSR was significantly more than control eyes (p = 0.04)
SFCT, MCVT and LCVT measurements are increased in eyes with acute CSR. However, thickening of medium choroidal vessels persists in chronic CSR. This is important in our understanding of disease activity in CSR, evaluation of chronicity of disease and development of structural end-points for clinical trials of treatments of CSR.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only